Research programme: antibody-drug conjugates - ADC Therapeutics/Cancer Research Technology/University of Copenhagen
Latest Information Update: 12 Jul 2016
At a glance
- Originator ADC Therapeutics; Cancer Research UK; University of Copenhagen
- Developer ADC Therapeutics; Cancer Research Technology; Cancer Research UK; University of Copenhagen
- Class Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Cancer